AnaptysBio, Inc.
ANAB
$19.89
-$0.27-1.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.06% | 13.89% | 11.24% | -12.07% | -18.12% |
| Total Depreciation and Amortization | 0.33% | 0.42% | 0.88% | 0.93% | 1.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 99.62% | 98.66% | 81.08% | 50.88% | 14.65% |
| Change in Net Operating Assets | -815.47% | -257.03% | -20,370.68% | -102.51% | -149.72% |
| Cash from Operations | 1.31% | 18.50% | -12.03% | -6.05% | -65.03% |
| Capital Expenditure | 25.90% | 44.46% | 55.64% | 46.58% | 14.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.81% | -67.35% | -34.22% | 48.03% | 168.32% |
| Cash from Investing | -44.88% | -67.47% | -34.10% | 48.60% | 170.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,451.26% | 4,871.31% | 3,979.37% | 1,686.94% | -72.89% |
| Repurchase of Common Stock | -- | 60.88% | 99.09% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -240.79% | 166.89% | 326.60% | 20.38% | -40.12% |
| Cash from Financing | -1.58% | 417.05% | 314.27% | 280.74% | 265.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -175.17% | 209.97% | 346.48% | 612.48% | 200.33% |